Prorenone

Prorenone (developmental code name SC-23133) is a steroidal antimineralocorticoid of the spirolactone group related to spironolactone that was never marketed.[1] It is the lactonic form of prorenoic acid (prorenoate), and prorenoate potassium (SC-23992), the potassium salt of prorenoic acid, also exists.[1] Prorenoate potassium is about 8 times more potent than spironolactone as an antimineralocorticoid in animals, and it may act as a prodrug to prorenone.[1] In addition to the mineralocorticoid receptor, prorenone also binds to the glucocorticoid, androgen, and progesterone receptors.[2][3] The antiandrogenic potency of prorenone in vivo in animals is close to that of spironolactone.[3] Similarly to spironolactone, prorenone is also a potent inhibitor of aldosterone biosynthesis.[4]

Prorenone
Clinical data
Other namesSC-23133; 3-(17β-Hydroxy-6β,7β-methylene-3-oxo-4-androsten-17α-yl)propionic acid γ-lactone
ATC code
  • None
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
ChemSpider
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC23H30O3
Molar mass354.490 g·mol−1
3D model (JSmol)

Chemistry

Synthesis

Prorenone can be synthesized via a Johnson–Corey–Chaykovsky reaction by reaction of canrenone with trimethylsulfonium iodide and sodium hydride.[5]

gollark: Oh nooooo, how horrible, people are designing high-heat reactors and using them on low-heat stuff...
gollark: <@222954376677949442> I don't see if it matters if people make HECf ones and run other fuels in them. Under the current rules they're worse than other designs for efficiency and stuff anyway.
gollark: What abuses?
gollark: Even if we assume reality is not arbitrary, the decisions about which bits of it to use are.
gollark: Reality is arbitrary!

See also

References
  1. Claire, M.; Rafestin-Oblin, M. E.; Michaud, A.; Roth-Meyer, C.; Corvol, P. (1979). "Mechanism of Action of a New Antialdosterone Compound, Prorenone*". Endocrinology. 104 (4): 1194–1200. doi:10.1210/endo-104-4-1194. ISSN 0013-7227. PMID 436757.
  2. Gyorgy Szasz; Zsuzsanna Budvari-Barany (19 December 1990). Pharmaceutical Chemistry of Antihypertensive Agents. CRC Press. pp. 87–. ISBN 978-0-8493-4724-5.
  3. Kamata S, Matsui T, Haga N, Nakamura M, Odaguchi K, Itoh T, Shimizu T, Suzuki T, Ishibashi M, Yamada F (September 1987). "Aldosterone antagonists. 2. Synthesis and biological activities of 11,12-dehydropregnane derivatives". J. Med. Chem. 30 (9): 1647–58. doi:10.1021/jm00392a022. PMID 3040999.
  4. Netchitailo, Pierre; Delarue, Catherine; Perroteau, Isabelle; Leboulenger, Francois; Capron, Michel-Hubert; Vaudry, Hubert (1985). "Relative inhibitory potency of five mineralocorticoid antagonists on aldosterone biosynthesis in vitro". Biochemical Pharmacology. 34 (2): 189–194. doi:10.1016/0006-2952(85)90123-6. ISSN 0006-2952. PMID 2981534.
  5. Chinn, L.; 1974, U.S. Patent 3,845,041



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.